Summary
Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemotherapy. Patients initially entered in the study received bleomycin 15 μ/m2 three times weekly for 8 weeks. This was later changed to 15 μ/m2 twice weekly for 8 weeks because of unacceptable stomatitis. Most patients had relapsed following surgery and/or radiotherapy, but none had received prior chemotherapy. A2: 1 randomization in favor of the dibromodulcitol-containing therapy was used. There were 12 partial responses in the 44 evaluable patients receiving the combination (27%), and 4 partial response in the 18 patients receiving single-agent bleomycin chemotherapy (22%). This difference was not statistically significant. Response durations were also relatively short for both therapies. Within the limitations of this study, we were unable to demonstrate that patient benfit resulted from the addition of dibromulcitol to bleomycin chemotherapy for this patient population.
Similar content being viewed by others
References
Andrews NC, Weiss AJ, Wilson W, Nealon T, (1974) Phase II study of dibromodulcitol (NSC-104800). Cancer Chemother Rep 58:653
Bennett JM, Reich SD (1979) Bleomycin. Ann Intern Med 90:945
Carter SK, Livingston RB (1981) The chemotherapy of head and neck cancer. In: Carter SK, Glatstein E, Livingston RB (eds) Principles of cancer treatment. McGraw-Hill, pp 640–651
Keyes JW Jr, Selawry OS, Hansen HH (1971) Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer. Cancer Chemother Rep 55:583
Ohnuma T, Holland JF, Sako K, Shedd DP (1972) Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) in squamous cell carcinoma in man. Cancer Chemother Rep 56:625
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Issell, B.F., Borsos, G., D'Aoust, J.C. et al. Dibromodulcitol plus bleomycin compared with bleomycin alone in head and neck cancer. Cancer Chemother. Pharmacol. 8, 171–173 (1982). https://doi.org/10.1007/BF00255478
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255478